AGP Executive Report
Last update: 10 hours agoCLL Treatment Update (EU/EEA): AbbVie says the European Commission has expanded the VENCLYXTO (venetoclax) label to allow fixed-duration first-line combinations with acalabrutinib (with or without obinutuzumab) and with ibrutinib—covering EU states plus Iceland, Norway, and Liechtenstein. Bladder Cancer (EU/EEA): The EU CHMP issued a positive opinion for perioperative pembrolizumab plus enfortumab vedotin, followed by adjuvant therapy after radical cystectomy for cisplatin-ineligible muscle-invasive bladder cancer; a final EC decision is expected in Q3 2026 for EU, Iceland, Liechtenstein, and Norway. Transplant Outcomes (Europe): Hansa Biopharma reports 90% one-year graft failure-free survival with Idefrix (imlifidase) in highly sensitised kidney transplant patients, with patient survival at 98% in a European post-authorisation study. Rare Immunodeficiency (EU/EEA): Pharming received EU marketing authorization for Joenja (leniolisib) for activated PI3K delta syndrome, approved for ages 12+ across the EU plus Norway, Iceland, and Liechtenstein. Health Access & Travel Rules (UK): The UK DWP confirms strict Personal Independence Payment holiday rules for trips over four weeks, warning of fines or payment stops if claimants don’t report changes.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
